Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease

Sheila A. Doggrel

    Research output: Contribution to journalComment/debate


    Asthma is a very common condition that can be managed well pharmacologically. In contrast, the presently available management of chronic obstructive pulmonary disease (COPD) is poor. The phosphodiesterase 4 inhibitor roflumilast has an anti-inflammatory effect, and has recently been shown to reduce the early and late responses in mild allergic asthma. Roflumilast may become a steroid-free option for those patients who do not tolerate or want to take long-term corticosteroids to prevent asthma. In COPD, roflumilast improved measures of pulmonary function, quality of life and well being. As the inflammation of COPD is resistant to corticosteroids, roflumilast has potential as an anti-inflammatory agent in the treatment of COPD. Roflumilast is generally well tolerated.
    Original languageEnglish
    Pages (from-to)485-488
    Number of pages4
    JournalExpert Opinion on Pharmacotherapy
    Issue number4
    Publication statusPublished - 2006


    Dive into the research topics of 'Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease'. Together they form a unique fingerprint.

    Cite this